From the other side of the consultation, briefly. If two explanations both fit, the useful question is which one predicts something the other does not. That is answerable; arguing about which sounds more plausible is not.
kate.chem said:With resmetirom now available for MASH, combination approaches are being explored, so the standard of care in this area is moving faster than most…
This is exactly what I could not find anywhere else.
Clinical perspective, offered as context rather than as advice. It helps to say which part of this you are uncertain about. A precise question gets a precise answer; a general one gets everybody’s favourite anecdote.
If somebody has the primary source to hand I would rather cite it than paraphrase it.
Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.
Shop Reference Standardspaige_pharma said:It helps to say which part of this you are uncertain about.
Same position here, arrived at the long way round. Steady state is the thing most people miss. The terminal half-life is about a week, so every dose step takes four to five weeks to fully express itself. Judging a step at day ten is judging the ascent, not the plateau, and it is the single commonest reason people escalate before they needed to.